GSK press releases Follow Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of relapsed/refractory multiple myeloma Second major approval for Blenrep combinations, with more expected in 2025 https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-combinations-approved-in-japan/ gsk.com
